Scinai Immunotherapeutics Ltd (SCNI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has a cash flow conversion efficiency ratio of -0.123x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.45 Million) by net assets ($11.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Scinai Immunotherapeutics Ltd market capitalisation for the company's overall valuation and market capitalisation.
Scinai Immunotherapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Scinai Immunotherapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scinai Immunotherapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their cash flow conversion efficiency. Explore Scinai Immunotherapeutics Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baumart Holdings Ltd
AU:BMH
|
-0.258x |
|
Virax Biolabs Group Limited Ordinary Shares
NASDAQ:VRAX
|
-0.576x |
|
Dixie Gold Inc
V:DG
|
-0.501x |
|
CT UK High Income Ord
LSE:CHI
|
0.007x |
|
Peel Hunt Ltd
LSE:PEEL
|
0.134x |
|
Mobile-health Network Solutions Class A Ordinary Shares
NASDAQ:MNDR
|
-0.508x |
|
Investment Friends Capital SE
WAR:IFC
|
0.002x |
|
Barakah Offshore Petroleum Bhd
KLSE:7251
|
0.017x |
Annual Cash Flow Conversion Efficiency for Scinai Immunotherapeutics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scinai Immunotherapeutics Ltd from 2006 to 2025. View Scinai Immunotherapeutics Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.10 Million | $-6.03 Million | -0.744x | -17.22% |
| 2024-12-31 | $9.98 Million | $-6.33 Million | -0.635x | -130.92% |
| 2023-12-31 | $-4.57 Million | $-9.38 Million | 2.053x | -50.25% |
| 2022-12-31 | $-1.76 Million | $-7.26 Million | 4.128x | +154.59% |
| 2021-12-31 | $982.00K | $-7.43 Million | -7.562x | -252.16% |
| 2020-12-31 | $-4.54 Million | $-22.57 Million | 4.970x | +319.55% |
| 2019-12-31 | $-18.84 Million | $-22.31 Million | 1.185x | -35.35% |
| 2018-12-31 | $-8.35 Million | $-15.29 Million | 1.832x | +1125.54% |
| 2017-12-31 | $16.17 Million | $-2.89 Million | -0.179x | +52.59% |
| 2016-12-31 | $6.65 Million | $-2.51 Million | -0.377x | -23.12% |
| 2015-12-31 | $8.61 Million | $-2.63 Million | -0.306x | +32.95% |
| 2014-12-31 | $4.26 Million | $-1.94 Million | -0.457x | -160.40% |
| 2013-12-31 | $6.92 Million | $-1.21 Million | -0.175x | +42.74% |
| 2012-12-31 | $5.95 Million | $-1.82 Million | -0.306x | +24.07% |
| 2011-12-31 | $6.71 Million | $-2.71 Million | -0.403x | -39.67% |
| 2010-12-31 | $7.94 Million | $-2.29 Million | -0.289x | -185.60% |
| 2009-12-31 | $8.44 Million | $-852.95K | -0.101x | -1862.97% |
| 2006-12-31 | $1.74 Million | $10.00K | 0.006x | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more